Entrada Therapeutics, Inc.
NASDAQ: TRDABoston, US · Founded 2016 · Delaware corporation · 6 known investors
Find your way into Entrada Therapeutics, Inc.
713 people in our graph share verified history with the Entrada Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.
Katrin Geyskensunlockedknows Nathan J. Dowden · together at The University of Chicago Booth School of Business (overlapped)
knows the team · via The University of North Carolina at Chapel Hill
knows the team · via Rubius Therapeutics
×4knows the team · via D'Amore-McKim School of Business at Northeastern University
knows the team · via Serono
knows the team · via Bluebird Bio
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells. Its pipeline spans discovery to clinical-stage treatments for retinal, neuromuscular, and metabolic diseases, including Duchenne muscular dystrophy.
Founders & leadership
NS
Natarajan SethuramaninExecutive
NK
Nerissa KreherinChief Medical Officer2020–2024Nerissa Kreher is a board-certified pediatric endocrinologist with experience in academic research, clinical practice, and biotechnology, including roles in medical affairs and clinical development. She holds an MBA and has expertise in rare disease therapeutics.
KW
Kory WentworthinChief Financial Officer and TreasurerKory Wentworth held senior finance leadership roles at research and commercial-stage biotech companies and Big 4 public accounting firms, with experience managing cross-functional teams and supporting global product launches and operational scaling. He serves as an Executive Officer at Entrada Therapeutics, which develops intracellular therapeutics for previously difficult-to-target diseases.
DD
Dipal DoshiinChief Executive Officer & Board MemberDipal Doshi has nearly 30 years of experience in the life sciences industry, including roles in business development, corporate strategy, and product commercialization at companies including Amicus Therapeutics and Catalent, and holds an MBA from Wharton and a BA from Rutgers University. He has been Chief Executive Officer of Entrada Therapeutics since 2017, building the clinical-stage biotech company focused on developing intracellular therapeutics.
ND
Nathan DowdeninPresident and Chief Operating OfficerNathan Dowden is Chief Operating Officer of Entrada Therapeutics, a biotech company developing intracellular therapeutics for genetic and metabolic diseases. He brings three decades of healthcare experience including prior roles in corporate development at Rubius Therapeutics, leadership of The Frankel Group life science consulting firm, and consulting at Huron and Ernst & Young in strategy and operations.
NS
Natarajan Sethuraman, PhDPresident of Research and Development
NJ
Nathan J. DowdeninPresident and Chief Operating OfficerNathan Dowden is President and Chief Operating Officer of Entrada Therapeutics. He brings 30 years of healthcare strategy and operations experience, including prior roles leading corporate development at Rubius Therapeutics, heading a life sciences consulting practice at Huron, founding and selling The Frankel Group, and positions at Ernst & Young, Searle Pharmaceuticals, and CIGNA Healthcare.
KW
Kory Wentworth, CPAChief Financial Officer
JC
Jared Cohen, PhD, JDinGeneral Counsel
KM
Karla MacDonaldinChief Corporate Affairs Officer
Board
CN
KM
Investors · 6
Reported raises · per SEC filings
Form D private placements$150.9M disclosed across 3 of 6 rounds · 1900–2021
▶$116.2MraisedApr 2021 · 26 investors · BiotechnologyRule 506(b)
▶$116.2MraisedApr 2021 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carole NuechterleinDirector
- Natarajan SethuramanExecutive Officer
- Kush M. ParmarDirector
- Todd FoleyDirector
- Peter KimDirector
- Nerissa KreherExecutive Officer
- Kory WentworthExecutive Officer
- Dipal DoshiExecutive Officer, Director
- John F. CrowleyDirector
- Nathan DowdenExecutive Officer
- Offering amount
- $116.2M
- Amount sold
- $116.2M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$34MraisedDec 2019 · 10 investors · PharmaceuticalsRule 506(b)
▶$34MraisedDec 2019 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Natarajan SethuramanExecutive Officer
- John CrowleyDirector
- Nathan DowdenExecutive Officer
- Louis TartagliaDirector
- Kush ParmarDirector
- Christine BrennanDirector
- Anja HarmeierDirector
- Dipal DoshiExecutive Officer, Director
- Todd FoleyDirector
- Mario SaltarelliExecutive Officer
- Offering amount
- $59M
- Amount sold
- $34M
- Proceeds to insiders
- $3.4M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$600KraisedNov 2016 · 2 investors · PharmaceuticalsRule 506(b)
▶$600KraisedNov 2016 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kush ParmarExecutive Officer, Director
- Louis TartagliaExecutive Officer, Director
- Dehua PeiDirector
- Offering amount
- $1.6M
- Amount sold
- $600K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$598.7Mvaluation at IPONov 2021 · $20.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Entrada Therapeutics, Inc. went on to found or lead other companies.
Competitors · 1
by search overlap
Companies competing with Entrada Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Entrada Therapeutics, Inc. do?
- Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells. Its pipeline spans discovery to clinical-stage treatments for retinal, neuromuscular, and metabolic diseases, including Duchenne muscular dystrophy.
- Who are Entrada Therapeutics, Inc.'s investors?
- Entrada Therapeutics, Inc.'s investors include 5AM Ventures, Agent Capital, MPM BioImpact, MRL Ventures Fund, Roche Venture Fund, TCG Crossover.
- How much funding has Entrada Therapeutics, Inc. raised?
- Entrada Therapeutics, Inc. has disclosed $150.9M raised across 3 of its 6 known rounds.
- Where is Entrada Therapeutics, Inc. headquartered?
- Entrada Therapeutics, Inc. is headquartered in Boston, US.